AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27618810 — intervention group
Group type: EXPERIMENTAL
Intervention: Family health history (FHH) feedback
Number of subjects: 150
Study 27618810 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-average family disease risk
Number of subjects: 150
Study 27618810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FHH feedback initially)
Number of subjects: 150
Study 24693784 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation and single PEEK Cage
Number of subjects: 126
Study 24693784 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation and single PEEK Cage
Number of subjects: 126
Study 22460385 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite 20% IVFE (composed of soybean, MCT, olive, and fish oils)
Number of subjects: 40
Study 22460385 — intervention group
Group type: COMPARATOR
Intervention: Conventional long-chain triglyceride (LCT)/MCT 20% IVFE
Number of subjects: 40
Study 20541381 — intervention group
Group type: EXPERIMENTAL
Intervention: NVA237 50 microg
Number of subjects: 83
Study 20541381 — intervention group
Group type: EXPERIMENTAL
Intervention: NVA237 100 microg
Number of subjects: 83
Study 20541381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 83
Study 20541381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 18678842 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV testing with the OraQuick ADVANCE Rapid HIV‐1/2 Antibody Test
Number of subjects: 849
Study 18678842 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot alone as a confirmation test
Number of subjects: 849
Study 18678842 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of HIV‐1 RNA testing to the confirmation protocol
Number of subjects: 849
Study 18678842 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive oral OraQuick HIV screening test
Number of subjects: 849
Study 16227898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing school entry back pain history
Number of subjects: 174
Study 16227898 — intervention group
Group type: EXPERIMENTAL
Intervention: First year in nursing school
Number of subjects: 174
Study 16227898 — intervention group
Group type: EXPERIMENTAL
Intervention: First year as a nurse
Number of subjects: 174
Study 16227898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifth year as a nurse
Number of subjects: 174
Study 16227898 — intervention group
Group type: EXPERIMENTAL
Intervention: Back pain history at entry to nursing school
Number of subjects: 174
Study 16227898 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in twisted/bent positions
Number of subjects: 174
Study 16227898 — intervention group
Group type: EXPERIMENTAL
Intervention: Working positions
Number of subjects: 174
Study 12892186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral THR
Number of subjects: 200
Study 12892186 — intervention group
Group type: COMPARATOR
Intervention: Unilateral THR
Number of subjects: 200
Study 12892186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented THR
Number of subjects: 200
Study 12892186 — intervention group
Group type: COMPARATOR
Intervention: Cementless THR
Number of subjects: 200
Study 12892186 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombi at six months
Number of subjects: 200
Study 12892186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary embolism
Number of subjects: 200
Study 10223771 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral ibuprofen
Number of subjects: 11
Study 10223771 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g of 5% ibuprofen gel (topical administration)
Number of subjects: 11
Study 8874256 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training program using a bicycle ergometer for 30 min 3 times a week at a load corresponding to 50 to 60% of peak oxygen consumption
Number of subjects: 27
Study 8874256 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training program
Number of subjects: 27
Study 8874256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in previous physical activity)
Number of subjects: 27
Study 1997515 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐min insulin pulses (1.3 mU kg‐1 min‐1, 2 min on and 11 min off)
Number of subjects: 9
Study 1997515 — intervention group
Group type: EXPERIMENTAL
Intervention: 26‐min insulin pulses (2.6 mU kg‐1 min‐1, 2 min on and 24 min off)
Number of subjects: 9
Study 1997515 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin (0.2 mU kg‐1 min‐1)
Number of subjects: 9
Study 6555065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administration for 3 days
Number of subjects: 12
Study 6555065 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal sodium intake
Number of subjects: 12
Study 6555065 — intervention group
Group type: COMPARATOR
Intervention: Control group with low sodium intake
Number of subjects: 12
Study 31242981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tualang honey 20mg daily for 8 weeks
Number of subjects: 40
Study 31242981 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C 100mg daily for 8 weeks
Number of subjects: 40
Study 28623766 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehomecare technology
Number of subjects: 116
Study 28623766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telehomecare technology)
Number of subjects: 116
Study 27206952 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day (MARINE)
Number of subjects: 760
Study 27206952 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day (ANCHOR)
Number of subjects: 760
Study 27206952 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day (ANCHOR, higher-efficacy group)
Number of subjects: 760
Study 27206952 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day (ANCHOR, medium-efficacy group)
Number of subjects: 760
Study 24844333 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 1126
Study 24844333 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1126
Study 21738241 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 30
Study 21738241 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical weight loss (gastric bypass)
Number of subjects: 30
Study 21738241 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 19514187 — intervention group
Group type: EXPERIMENTAL
Intervention: NGF injection at Yifeng (TE 17) and Wangu (GB 12)
Number of subjects: 140
Study 19514187 — intervention group
Group type: COMPARATOR
Intervention: Xibiling and adenosine triphosphate (ATP) orally, and intramuscular injection with VB1 and VB12
Number of subjects: 140
Study 17766700 — intervention group
Group type: COMPARATOR
Intervention: Enzastaurin (single doses 2-400 mg)
Number of subjects: 46
Study 17766700 — intervention group
Group type: COMPARATOR
Intervention: Enzastaurin (multiple doses 25-400 mg)
Number of subjects: 46
Study 15801497 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-implement training (bowling with overweight and underweight cricket balls)
Number of subjects: 16
Study 15801497 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (bowling with regulation cricket balls)
Number of subjects: 16
Study 15801497 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-implement training
Number of subjects: 16
Study 15801497 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 16
Study 11526657 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 96
Study 11526657 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis (Control)
Number of subjects: 96
Study 9561984 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI studies in patients with LNS
Number of subjects: 7
Study 9561984 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric studies of patients with LNS
Number of subjects: 7
Study 7909866 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment with 500 mg of 17‐1A antibody, followed by four 100 mg infusions each month
Number of subjects: 189
Study 3108534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid
Number of subjects: 18
Study 3108534 — intervention group
Group type: COMPARATOR
Intervention: Soyacal
Number of subjects: 18
Study 3108534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lipid emulsions
Number of subjects: 18
Study 29869350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 70
Study 29869350 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 70
Study 27451879 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (2.5 g before every meal for 48 weeks)
Number of subjects: 40
Study 23983196 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint distraction
Number of subjects: 111
Study 22419702 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg two times daily for obese women; 500 mg + 1000 mg daily for nonobese)
Number of subjects: 320
Study 22419702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical doses)
Number of subjects: 320
Study 22419702 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in obese women)
Number of subjects: 320
Study 22419702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in obese women)
Number of subjects: 320
Study 22419702 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in nonobese women)
Number of subjects: 320
Study 22419702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in nonobese women)
Number of subjects: 320
Study 22419702 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus standard infertility treatment
Number of subjects: 320
Study 19669678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly administration)
Number of subjects: 2
Study 19669678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (as-needed basis)
Number of subjects: 2
Study 19669678 — intervention group
Group type: COMPARATOR
Intervention: Pegaptanib
Number of subjects: 2
Study 18441450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (group A)
Number of subjects: 93
Study 18441450 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate (group B)
Number of subjects: 93
Study 16192479 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg per day)
Number of subjects: 95
Study 16192479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg every 12 hours)
Number of subjects: 95
Study 16192479 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 95
Study 16192479 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups post-surgery
Number of subjects: 95
Study 16192479 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 95
Study 12761364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 132
Study 12761364 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 132
Study 10823763 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of prophylaxis (n=355)
Number of subjects: 708
Study 10823763 — intervention group
Group type: COMPARATOR
Intervention: Continuation of prophylaxis (n=353)
Number of subjects: 708
Study 8651713 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% glycolic acid cream
Number of subjects: 74
Study 8651713 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% L-lactic acid cream
Number of subjects: 74
Study 8651713 — intervention group
Group type: COMPARATOR
Intervention: vehicle cream
Number of subjects: 74
Study 1995051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5 mg/kg intravenously prior to induction
Number of subjects: 15
Study 1995051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lignocaine)
Number of subjects: 15
Study 6400414 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 6
Study 6400414 — intervention group
Group type: COMPARATOR
Intervention: Placebo plasma exchange
Number of subjects: 6
Study 31722941 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 540,000 IU cholecalciferol followed by 4000 IU daily for 90 days
Number of subjects: 2400
Study 31722941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study 30371293 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB continuation
Number of subjects: 126
Study 26597254 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate/Amodiaquine (AS/AQ)
Number of subjects: 602
Study 26597254 — intervention group
Group type: COMPARATOR
Intervention: Artemether/Lumefantrine (AL)
Number of subjects: 602
Study 24838369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg of ethanol
Number of subjects: 65
Study 24838369 — intervention group
Group type: COMPARATOR
Intervention: No ethanol
Number of subjects: 65
Study 22726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) administered at a dose of ≥20 UI/kg with vitamin K
Number of subjects: 256
Study 22726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) administered at a dose of >20 UI/kg
Number of subjects: 256
Study 22726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) for major hemorrhages
Number of subjects: 256
Study 22726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) administration
Number of subjects: 256
Study 20109697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin once daily
Number of subjects: 100
Study 20109697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16889639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone pulse (IVGC)
Number of subjects: 52
Study 16889639 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone (OGC)
Number of subjects: 52
Study 15953135 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP group (n = 136)
Number of subjects: 269
Study 15953135 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 133)
Number of subjects: 269
Study 12519218 — intervention group
Group type: EXPERIMENTAL
Intervention: AOC7 (1000 mg amoxicillin, 20 mg omeprazole, and 500 mg clarithromycin twice daily for 7 days)
Number of subjects: 128
Study 12519218 — intervention group
Group type: EXPERIMENTAL
Intervention: FOT4 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 4 days)
Number of subjects: 128
Study 12519218 — intervention group
Group type: EXPERIMENTAL
Intervention: FOT7 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 7 days)
Number of subjects: 128
Study 10862549 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly supervised heavy-resistance training (SUP)
Number of subjects: 20
Study 10862549 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised training (UNSUP)
Number of subjects: 20
Study 8892160 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral approach
Number of subjects: 48
Study 8892160 — intervention group
Group type: COMPARATOR
Intervention: Behavioral approach preceded by surgery
Number of subjects: 48
Study 8892160 — intervention group
Group type: COMPARATOR
Intervention: Behavioral approach without preceding surgery
Number of subjects: 48
Study 8892160 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after failed behavioral treatment
Number of subjects: 48
Study 2051405 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate introduced below the scleral and conjunctival flaps
Number of subjects: 0
Study 2051405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium hyaluronate)
Number of subjects: 0
Study 6209318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 630
Study 6209318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study 31767474 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with 66 Gy (24x2.75 Gy) and low dose Cisplatin +/− Cetuximab
Number of subjects: 47
Study 31767474 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment PET-metrics (SUVmax, SUVmean, MTV, TLG)
Number of subjects: 47
Study 31767474 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative response of TLG/MTV
Number of subjects: 47
Study 29902612 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 139
Study 29902612 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib after cross-over
Number of subjects: 139
Study 29902612 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed regorafenib
Number of subjects: 139
Study 28003538 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein supplementation (0, 20, 40, or 60 g WP/d)
Number of subjects: 186
Study 28003538 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Protein intake (TPro)
Number of subjects: 186
Study 28003538 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Total Protein intake (postsupplementation - presupplementation)
Number of subjects: 186
Study 26030325 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 355
Study 26030325 — intervention group
Group type: COMPARATOR
Intervention: Add-on ezetimibe 10 mg/d
Number of subjects: 355
Study 26030325 — intervention group
Group type: COMPARATOR
Intervention: Doubling atorvastatin dose
Number of subjects: 355
Study 26030325 — intervention group
Group type: COMPARATOR
Intervention: Switching atorvastatin 40 mg to rosuvastatin 40 mg
Number of subjects: 355
Study 23988337 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary care intervention
Number of subjects: 301
Study 23988337 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 301
Study 20354035 — intervention group
Group type: EXPERIMENTAL
Intervention: sivelestat 0.2 mg/kg/h
Number of subjects: 12
Study 20354035 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 12
Study 18373854 — intervention group
Group type: EXPERIMENTAL
Intervention: High-referring clinicians
Number of subjects: 0
Study 18373854 — intervention group
Group type: COMPARATOR
Intervention: Non-referring clinicians
Number of subjects: 0
Study 17240782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey isolate (WI)
Number of subjects: 13
Study 17240782 — intervention group
Group type: COMPARATOR
Intervention: Casein (C)
Number of subjects: 13
Study 12605628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy group
Number of subjects: 10
Study 12605628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 10706930 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (long‐cycle transdermal 17‐beta‐estradiol 50 microg/24 hour for 3 months with sequential medroxy‐progesterone acetate for 14 days)
Number of subjects: 118
Study 10706930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 118
Study 10706930 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 118
Study 8931030 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly structured exercise program
Number of subjects: 179
Study 8931030 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 179
Study 1442974 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel plus ethinyl estradiol
Number of subjects: 52
Study 1442974 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone plus ethinyl estradiol
Number of subjects: 52
Study 1442974 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 52
Study 6430329 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids (L‐cysteine, glycine, DL‐threonine)
Number of subjects: 0
Study 31654294 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg QD
Number of subjects: 1270
Study 31654294 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg BID
Number of subjects: 1270
Study 31654294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1270
Study 29692236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac High Acuity Monitoring Program (CHAMP)
Number of subjects: 31
Study 29692236 — intervention group
Group type: COMPARATOR
Intervention: Three-ring binder monitoring (Binder)
Number of subjects: 31
Study 27955652 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care in the delivery room
Number of subjects: 0
Study 27955652 — intervention group
Group type: COMPARATOR
Intervention: Incubator (standard care)
Number of subjects: 0
Study 24176943 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral therapy (ART) during TB treatment
Number of subjects: 501
Study 24176943 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of antiretroviral therapy (ART) during TB treatment
Number of subjects: 501
Study 24176943 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard first-line antiretrovirals (efavirenz, lamivudine, didanosine)
Number of subjects: 501
Study 24176943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CD4(+) T-cell count <50 cells/mm(3) at ART initiation
Number of subjects: 501
Study 24176943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with body mass index >25 kg/m(2) at entry into the study
Number of subjects: 501
Study 22351711 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic collection of family history through a questionnaire in intervention practices
Number of subjects: 748
Study 22351711 — intervention group
Group type: COMPARATOR
Intervention: Usual Framingham‐based cardiovascular risk assessment without systematic family history collection in control practices
Number of subjects: 748
Study 22351711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 748
Study 20578825 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for one year
Number of subjects: 23
Study 20578825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23